Sanofi $SNY Stake Cut by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lessened its holdings in Sanofi (NASDAQ:SNY) by 91.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,492 shares of the company’s stock after selling 67,064 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Sanofi were worth $313,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SNY. Flagship Harbor Advisors LLC bought a new position in shares of Sanofi in the 4th quarter worth about $25,000. Physician Wealth Advisors Inc. grew its position in shares of Sanofi by 180.5% during the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after buying an additional 379 shares during the last quarter. Leonteq Securities AG grew its position in shares of Sanofi by 95.8% during the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after buying an additional 297 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in Sanofi during the third quarter worth about $29,000. Finally, Palisade Asset Management LLC acquired a new stake in Sanofi during the third quarter worth about $30,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Up 1.2%

Sanofi stock opened at $43.68 on Thursday. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average price of $43.30 and a two-hundred day moving average price of $45.56. The firm has a market capitalization of $105.90 billion, a price-to-earnings ratio of 12.20, a PEG ratio of 1.10 and a beta of 0.34. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68.

Wall Street Analyst Weigh In

A number of equities analysts have commented on SNY shares. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a research note on Monday, April 20th. Morgan Stanley set a $49.00 price target on Sanofi in a research report on Wednesday, July 8th. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $49.50.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.